酒石酸美托洛尔治疗扩张型心肌病的疗效观察

Analysis of clinical treatment status of 78 cases patients with dilated cardiomyopathy

目的:分析酒石酸美托洛尔治疗扩张型心肌病的临床治疗效果。方法:选取78例扩张型心肌病患者,随机分为对照组和观察组,每组各39例。对照组患者接受常规抗心律失常治疗,观察组患者在常规治疗基础上辅以酒石酸美托洛尔治疗。对比分析两组患者治疗前后心率(HR)、24 h尿量、左室射血分数(LVEF)和临床疗效的差异性。结果:与治疗前比较,经过治疗后患者HR有所下降,24 h尿量、LVEF有所增加,其中观察组患者各指标改善幅度明显大于对照组,两组间差异有统计学意义(P<0.05);观察组患者总有效率明显高于对照组,两组间差异有统计学意义(P<0.05)。结论:在扩张型心肌病治疗期间辅以β受体阻滞剂酒石酸美托洛尔治疗,可有效改善心功能,对患者的预后有益。

Objective： To analyze clinical treatment effects and status of patients with dilated cardiomyopathy （DCM）. Methods： 78 cases patients with DCM were randomly divided into observation group and control group, 39 cases in each group. The control group patients received routine anti-arrhythmic treatment; while on the basis of conventional treatment, the observation group patients were given tartaric acid metoprolol tartrate therapy. A contrastive analysis of the two groups before and after the treatment in heart rate （HR）, 24 h urine, left ventricular ejection fraction （LVEF） and the clinical curative effects was performed. Results： Compared with those before the treatment, the HR declined, 24 h urine and LVEF increased after the treatment. The index improvement of observation group was significantly greater than that of control group, and t test analysis found that the difference between the two groups was statis- tically significant （ P〈0.05 ）. The total effective rate of observation group was significantly higher than that of control group, and chisquare analysis found that the difference between the two groups was statistically significant （P〈0.05）. Conclusions： During the treatment with beta-blockers in DCN, metoprolol tartrate therapy added can effectively improve cardiac function, and is beneficial to the prognosis of the patients.